Who is sponsoring NCT02752633?

NCT02752633 is sponsored by Landspitali University Hospital.

What condition does NCT02752633 study?

NCT02752633 studies Adenine Phosphoribosyltransferase Deficiency.

What drugs are being tested in NCT02752633?

Interventions: Allopurinol, Febuxostat.

What is the status of NCT02752633?

NCT02752633 is currently COMPLETED.

Last reviewed 2024-04-08 · How we verify

A Novel Assay for the Determination of Urinary 2,8-Dihydroxyadenine and Other Key Urinary Purine Metabolites: Effect of Allopurinol and Febuxostat on Urinary 2,8-Dihydroxyadenine Excretion in APRT Deficient Patients

NCT02752633 Phase 4 COMPLETED Results posted

This exploratory pilot study was an open-label, crossover, single-center and non-randomized clinical trial designed to compare the effect of the standardly employed doses of allopurinol (400 mg/day) and febuxostat (80 mg/day) on the urinary 2,8-dihydroxyadenine (DHA) excretion in patients with adenine phosphoribosyltransferase (APRT) deficiency.

Details

Lead sponsor	Landspitali University Hospital
Phase	Phase 4
Status	COMPLETED
Enrolment	9
Start date	2013-05
Completion	2015-05

Conditions

Adenine Phosphoribosyltransferase Deficiency

Interventions

Allopurinol
Febuxostat

Primary outcomes

Urinary 2,8-dihydroxyadenine Excretion — 7, 21 and 42 days

Countries

Iceland